These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35738174)

  • 1. In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
    Abdelkader A; Elzemrany AA; El-Nadi M; Elsabbagh SA; Shehata MA; Eldehna WM; El-Hadidi M; Ibrahim TM
    Virology; 2022 Aug; 573():96-110. PubMed ID: 35738174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis.
    Pandey P; Prasad K; Prakash A; Kumar V
    J Mol Med (Berl); 2020 Dec; 98(12):1659-1673. PubMed ID: 32965508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach.
    Alshawaf E; Hammad MM; Marafie SK; Ali H; Al-Mulla F; Abubaker J; Mohammad A
    Microb Pathog; 2022 Sep; 170():105701. PubMed ID: 35963279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase.
    Piplani S; Singh P; Winkler DA; Petrovsky N
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2.
    Mohammad A; Alshawaf E; Marafie SK; Abu-Farha M; Al-Mulla F; Abubaker J
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation.
    Hu LC; Ding CH; Li HY; Li ZZ; Chen Y; Li LP; Li WZ; Liu WS
    J Food Biochem; 2022 May; 46(5):e14085. PubMed ID: 35128681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Putative SARS-CoV-2 M
    Mazzini S; Musso L; Dallavalle S; Artali R
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
    Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders.
    Moraca F; Marzano S; D'Amico F; Lupia A; Di Fonzo S; Vertecchi E; Salvati E; Di Porzio A; Catalanotti B; Randazzo A; Pagano B; Amato J
    Chem Commun (Camb); 2022 Oct; 58(85):11913-11916. PubMed ID: 36196950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
    Yuda GPWC; Hanif N; Hermawan A
    Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein.
    Eskandari V
    J Mol Model; 2022 May; 28(6):153. PubMed ID: 35578055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
    Kwofie SK; Broni E; Asiedu SO; Kwarko GB; Dankwa B; Enninful KS; Tiburu EK; Wilson MD
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33466743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.